Compare AbCellera Biologics Inc (ABCL) vs Hershey Co (HSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Hershey Co — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Hershey Co trades at $176.05 (market cap $35.69B). The key difference: Hershey Co is far larger — about 15.2× AbCellera Biologics Inc's market cap, and Hershey Co pays a 3.3% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HSY | |
|---|---|---|
Market Cap | $2.35B | $35.69B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $236.28 |
52-Week Low | $2.78 | $161.95 |
Enterprise Value | $1.99B | $40.49B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Hershey (HSY) trades at $175.95, down 3.4% over the past day, with a bearish technical signal but strong recent earnings beats. The stock shows a high P/E ratio of 33.06 and a net income margin of 9.12%, supported by consistent cash flow from operations of $2.28B in 2025. Recent corporate actions include a $1.45 dividend and executive appointments, while cocoa cost pressures show signs of easing according to MarketBeat (July 1, 2026).
The outlook is mixed: analyst consensus targets $211.27 with 65.72% hold ratings, indicating cautious optimism amid valuation concerns. Key risks include commodity inflation and competitive pressures, but margin recovery and dividend yield near 3.2% offer potential for income-focused investors. Upside depends on sustained earnings growth and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
